Monday, 24 October 2016

Iron Deficiency Anemia Treatment Pipeline Review H2 2016

The report provides comprehensive information on the therapeutics under development for Iron Deficiency Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Iron Deficiency Anemia and features dormant and discontinued projects.

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

- The report provides a snapshot of the global therapeutic landscape of Iron Deficiency Anemia
- The report reviews pipeline therapeutics for Iron Deficiency Anemia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Iron Deficiency Anemia therapeutics and enlists all their major and minor projects
- The report assesses Iron Deficiency Anemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Iron Deficiency Anemia

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Iron Deficiency Anemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Iron Deficiency Anemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Iron Deficiency Anemia Overview 7
Therapeutics Development 8
Pipeline Products for Iron Deficiency Anemia - Overview 8
Pipeline Products for Iron Deficiency Anemia - Comparative Analysis 9
Iron Deficiency Anemia - Therapeutics under Development by Companies 10
Iron Deficiency Anemia - Therapeutics under Investigation by Universities/Institutes 11
Iron Deficiency Anemia - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Iron Deficiency Anemia - Products under Development by Companies 15
Iron Deficiency Anemia - Products under Investigation by Universities/Institutes 16
Iron Deficiency Anemia - Companies Involved in Therapeutics Development 17
Galenica Ltd. 17
Johnson & Johnson 18
Novartis AG 19
Panion & Bf Biotech Inc 20
Pieris Pharmaceuticals, Inc. 21
Rockwell Medical, Inc. 22
Iron Deficiency Anemia - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
CSJ-137 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Drug to Repalce Iron for Iron Deficiency Anemia - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
ferric carboxymaltose - Drug Profile 34
Product Description 34
Mechanism Of Action 34

Contact Info:
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)                                                   

Get in touch:

No comments:

Post a Comment